Add BrightSurf on Google Email

Science News for June 4, 2002


Studies call for quality assurance in selecting candidates for herceptin trials

Two studies found high discordance between local laboratory tests and central testing facilities, raising concerns about patient eligibility for trastuzumab trials. These discrepancies could lead to unnecessary costs and cardiotoxicity. Trials have since modified their criteria to require central laboratory testing to confirm HER2 status.

SourceJournal of the National Cancer Institute·JournalJNCI Journal of the National Cancer Institute·DateJun 4, 2002

Putting cancer in context

A new report by Dartmouth and VA researchers has introduced simple, low-tech risk charts that place cancer mortality in context. These charts show the 10-year chance of dying from various causes, such as heart disease, stroke, or breast cancer, side-by-side for men and women of different ages and smoking statuses.

SourceThe Geisel School of Medicine at Dartmouth·JournalJNCI Journal of the National Cancer Institute·DateJun 4, 2002

Stanford researcher identifies genes pointing to liver cancer

Researchers at Stanford University Medical Center have identified genes needed by cancerous liver cells but ignored or used at different levels by normal liver cells. This discovery could lead to more effective treatments and screening tests for liver cancer in Asian populations, who are 10 times more likely to develop the disease due ...

SourceStanford Medicine·JournalMolecular Biology of the Cell·DateJun 4, 2002

Scaling up smart structures

A new approach to designing smart structures has been developed, using embedded systems with microprocessors and sensors. The system allows for scalability without increasing weight, power consumption, or cost, making it a promising solution for industries such as aerospace and automotive.